… anticoagulation for all hospitalized patients with COVID‐19, with most recommending use of
low‐molecular‐weight heparin or unfractionated heparin. … of 460 000 deaths worldwide as of …

… -molecular weight and unfractionated heparin, but not all patients … a decrease in mortality
of critical COVID-19 patients with … of the patients received rivaroxaban and the rest apixaban. …

… anticoagulation in COVID-19 patients and its effects on venous and arterial thrombosis, DIC,
and mortality [… prophylaxis with enoxaparin 0.5 mg/kg SQ daily or heparin 5000 units SQ …

… heparin (UFH) and low molecular weight heparin (LMWH). … COVID-19 outpatients randomized
to aspirin, apixaban 2.5 mg … the morbidity and mortality of COVID-19 infected patients will …

… with a significant reduction in mortality among patients with COVID-19 [23]. Yuan … heparin
(UFH) and newer direct oral anticoagulants (DOACs) (ie betrixaban, rivaroxaban and apixaban…

… associated with significant morbidity and mortality, and is the third … ‐weight heparin is not
necessary with apixaban. Therefore, … parenteral anticoagulants and oral anticoagulants such as …

… at Northwestern Medicine: apixaban, argatroban, bivalirudin, … molecular weight heparin
(LMWH) or heparin, respectively (… a higher mortality rate among patients with COVID-19 who …

… have determined the effects of anticoagulants by comparing the morbidity and mortality in …
daily while subcutaneous anticoagulation was (low-molecular-weight heparin- clexane 40mg …

… therapeutic anticoagulation with mortality for patients with COVID-19 … Therapeutic
anticoagulation was defined as apixaban, … anticoagulation was defined as subcutaneous heparin …

… , heparin may have prevented the swift increase in mortality … received therapeutic dose
anticoagulation -enoxaparin was the … prophylaxis and apixaban for therapeutic anticoagulation. In …